ORIC Pharmaceuticals, Inc., a clinical-stage oncology company, announced a private placement of approximately 19.2 million shares of its common stock, offered at $6.50 per share, to institutional and accredited healthcare specialist investors. This sale represents an 18% premium to ORIC's 10-day trailing volume-weighted average price as of May 23, 2025. The financing, expected to close on May 29, 2025, is anticipated to generate gross proceeds of approximately $125 million. The funds will support the development of ORIC's clinical-stage product candidates and research programs, and are projected to sustain operations through the second half of 2027, including the primary endpoint readout from the ORIC-944 Phase 3 trial in prostate cancer. The financing round is led by SR One, with participation from notable investors including Point72, Viking Global Investors, and NEA.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。